Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Seltorexant in Healthy Elderly, Young, and Japanese Adults
NCT02837692Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of seltorexant in Insomnia and major depressive disorder (MDD) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Jun 2016; status: completed.
02
Drugs
seltorexant
03
Conditions
Insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02837692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837692.